26 results on '"Paris, Laura"'
Search Results
2. Immagini di un’epoca
3. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
4. Vector control for malaria prevention during humanitarian emergencies: a systematic review and meta-analysis
5. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
6. Foundations of hemophilia and epidemiology
7. Anticoagulation and Antiplatelet Regimen in Cardiac Transplant. Clinical Characteristics, Outcomes, and Blood Product Transfusion.
8. Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study.
9. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
10. Associated Cancers in Waldenström Macroglobulinemia: Clues for Common Genetic Predisposition
11. P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY.
12. Treating multiple myeloma in the era of new drugs: What is the right choice?
13. Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy
14. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
15. Body Dissatisfaction and Disordered Eating in Three Cultures: Argentina, Brazil, and the U.S.
16. Estrategias de afrontamiento del estres como potenciadoras de bienestar
17. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study.
18. Safety of outpatient stem cell mobilization with low‐ or intermediate‐dose cyclophosphamide in newly diagnosed multiple myeloma patients.
19. Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use.
20. P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL.
21. A Rare Case of Atypical Palatal‐Lingual Tremor Associated with Waldenström's Macroglobulinemia.
22. CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
23. Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis.
24. VALIDACIÓN DEL INVENTARIO DE BIENESTAR SUBJETIVO CON MUESTRAS DE JÓVENES Y ADOLESCENTS ARGENTINOS, BRASILEROS Y MEXICANOS.
25. Newly-Diagnosed, Non-Transplant Eligible Multiple Myeloma Patients: Determinants of Choice of First-Line Treatment in a Single-Center.
26. OCEANAGE (ANOTHER GENERATION OF EXPLORERS): CAREER FEATURE ON NOAA's OCEAN EXPLORER WEBSITE.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.